Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Categories (click each to see list of all clinical trials associated with that category): Brain/Neuro (ONC), GI (ONC), GU (ONC), Gyn/Onc (OB/GYNONC), Head & Neck (ONC), Lymphoma/CLL (ONC), Melanoma (ONC), Sarcoma (ONC), Thoracic (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Marr, Alissa
Contact Information:
Brandie Booker, RN
402-559-8197
brandie.booker@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT02693535?term=NCT02693535&rank=1
Summary
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.